Kornimate/medical-research-clean huggingface dataset:
novel predictors of premature aging in copd patients

Conditions: COPD

Summary: •examine whether copd is associated with accelerated aging using a biological marker of aging and dermatological score

chronic obstructive pulmonary disease (copd) results from gene(g)-environment(e) interactions occurring over the lifetime(t) of the individual (getomics) that can damage the lungs and/or alter their normal development/aging processes. in copd, processes including oxidant/antioxidant, protease/antiprotease, and proliferative/ antiproliferative balance, and the control of the inflammatory response become dysfunctional, as in aging. a close relationship between the pathogenesis of copd and aging has been reviewed, and an increase regarding aging has been identified aging is defined as a time-dependent progressive loss of physiological integrity, resulting in impaired function and increased vulnerability to death many chronic diseases are dependent on age and encompass physiological mechanisms related to the aging process the interconnection of the different markers of aging has not yet been studied in clinical subjects. we hypothesized that these markers, representing different interrelated aspects of the aging process, are altered in a cohort of copd patients compared to the control group. these markers include growth hormone(gh), "red cell distribution width (rdw) and scinexa (score for intrinsic and extrinsic skin aging) score as a read-out of biological age. scinexa is a validated score which measures the intrinsic and extrinsic factors regarding chronological skin aging and aging due to chronic exposure to ultraviolet (uv) radiation, respectively. the major feature of aging is the role of hormones as key regulators of human muscle metabolism and physical function. growth hormone (gh) actions impact growth, metabolism, and body composition and have been associated with aging and longevity. while, red cell distribution width (rdw), a part of the standard complete blood count (cbc), is a simple and non-invasive parameter that can be used as a biomarker in evaluating the severity and mortality rates in copd patients in acute attacks. also, elevated rdw has been associated with degenerative conditions in aging.

Eligibility criteria:
inclusion criteria: * patients with copd attending outpatient are eligible for inclusion as cases. control group is non copd healthy controls. exclusion criteria: * • patients refused to participate in the study. * patients unable to perform the spirometry test. * patients had a history of hormone disorder or malignant disease. * patients received hormone replacement therapy.

Keywords: premature aging
pharmacokinetic, pharmacodynamic and tolerability study of otamixaban in patients with mild and moderate hepatic impairment

Conditions: Hepatic Impairment

Summary: primary objective: - to study effect of mild and moderate hepatic impairment on the pharmacokinetics of otamixaban. secondary objective: - to assess the pharmacodynamic effects of otamixaban on subjects with mild and moderate hepatic impairment and in matched subjects with normal hepatic function.

the duration of each part of the study for one subject was 28 days of screening, 1 day of treatment, with 5 days in the unit (day -1 to day 4) and a 8 to 11 days of follow-up after start of infusion.

Eligibility criteria:
inclusion criteria: - subjects with hepatic impairment: * body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 100.0 kg inclusive if female, body mass index between 18.0 and 34.9 kg/m2 inclusive * stable chronic liver disease assessed by medical history, physical examination, laboratory values * vital signs, cardiac function and laboratory parameters within the acceptable range for subjects with hepatic impairment * if female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal * patients with hepatic impairment will be matched to healthy subjects who are defined as healthy by physical examination, medical history and laboratory findings and are matched to patients with respect to age, gender, and body weight. inclusion/exclusion criteria for healthy subjects may differ slightly from those listed for patients and are defined in the study protocol exclusion criteria: * uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness * creatinine level above the upper limit of normal * hepatocarcinoma * acute hepatitis * hepatic encephalopathy grade 2, 3 and 4 * history or presence of drug or alcohol abuse within two years before inclusion * smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking during the institutionalization * any significant change in chronic treatment medication within 14 days before inclusion the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
clinical, biochemical and body composition analysis in assessment of steatosis in non alcoholic fatty liver disease

Conditions: Non-alcoholic Fatty Liver Disease NAFLD

Summary: non-alcoholic fatty liver disease (nafld) includes a spectrum of liver disorders characterized by accumulation of hepatic fat in absence of significant alcohol consumption (\<20 gm/day) and other causes of liver diseases. it is the most common cause of asymptomatic elevation of liver enzymes worldwide (marchesini et al., 2003). unfortunately, to date, existing non- or minimally invasive biomarkers are inadequate. while a number of non- or minimally invasive tests are able to rule out ﬁbrosis or cirrhosis, no single test to identify steatosis, to early diagnose nash, or to predict the disease progression is available. moreover, specialized, combined tests are required to assess treatment response in clinical trials on emerging compounds (piazzolla and mangia, 2020). among minimally invasive tools, plasma biomarkers and composite scores defined as "wet biomarkers" are commonly used. for example, fasting insulin level and its use in measurement of insulin resistance, lipid accumulation product (lap) score (bedogni et al., 2010), the nafld liver fat score (nlfs) (kontronen et al., 2009), hepatic steatosis index (hsi) (lee et al., 2010), controlled attenuation parameter (cap) measurement by fibroscan (piazzolla and mangia, 2020). recent studies have shown that cap signiﬁcantly correlates with the percentage of steatosis and steatosis grade and that median cap is higher among patients with signiﬁcant steatosis (sasso et al., 2012 \& karlas et al., 2017). the prevalence of nafld is 80-90% in obese, 30-50% in patients with diabetes and up to 90% in patients with hyperlipidemia (abenavoli et al., 2014) central obesity or visceral fat (vf) (determined by waist circumference (wc)) is defined as the presence of excess fat in the abdomen, and this type of obesity is often associated with the development and progression of nafld or more advanced forms of liver disease (abenavoli et al., 2016). thus, measurement of body composition rather than bmi may be helpful in the prediction of nafld (milić et al., 2014 and abenavoli et al., 2016) there is a growing need to assess the steatosis in nafld patients using minimally invasive tools.


Eligibility criteria:
inclusion criteria: * adult subjects with bright liver by abdominal ultrasound will be recruited. * the diagnosis will be based on cap score result measured by fibroscan. exclusion criteria: * alcohol consumption. * patients with other liver diseases as acute and chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, drug-induced hepatitis. * decompensated liver disease. * other end organ failure. * pregnancy. * patients on statins or fenofibrate.

Keywords: non-alcoholic fatty liver disease nafld
study pilot - hybrid eeg/fmri neurofeedback in depressed patients

Conditions: Depression

Summary: cognitive impairment is a common residual symptom after a depressive episode and expose patients to a risk of relapsing or therapeutic resistance. neurofeedback (using electroencephalography - eeg or functional magnetic resonance imaging - fmri) allows patients to self-regulate their cerebral activity, which is supposedly provided through an intelligible and motivating feedback. recent results exhibited clinical improvement in depressed patients who underwent a fmri neurofeedback protocol targeting the amygdala. furthermore, prefrontal alpha activity was temporally correlated to variations of the bold signal in the amygdala. simultaneous fmri/eeg neurofeedback is hypothesized to potentialize its antidepressant effect. our objective will be to test this assumption by conducting a double-blind randomized trial, and to prove the superiority of bimodal fmri/eeg neurofeedback over fmri neurofeedback alone in depressed patients. an original visual feedback will be provided and validated beforehand by a pilot study.


Eligibility criteria:
inclusion criteria: 1. aged 18 to 65 years old 2. signature of an informed consent after being given clear and loyal oral and written information exclusion criteria: related to the volunteer 1. prior experience of a neurofeedback task related to the mri 2. implanted cardiac pacemaker of defibrillator 3. brain aneurysm clip 4. cochlear implant 5. ocular on encephalic metallic foreign body 6. endoprothesis implanted for less than 4 weeks and ostheosynthesis device implanted for less than 6 weeks. 7. claustrophobia other criteria 8. unstable hemodynamic status 9. acute respiratory failure 10. alteration of general state or continuous monitoring requirement 11. other psychiatric condition (dsm-5) such as schizophrenia, substance abuse... 12. neurological condition or diagnosis of dementia in medical history 13. undergoing treatment by benzodiazepines or anticonvulsants prescribed less than a month prior to inclusion 14. undergoing treatment influencing the blood flow prescribed less than three weeks prior to inclusion 15. protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)

Keywords: neurofeedback
the eye patch and headset on sleep quality, anxiety, fear and vital signs

Conditions: Intensive Care Unit Syndrome

Summary: this study was planned to investigate the effects of eye patch and headphones on sleep quality, anxiety, fear and vital signs in coronary intensive care unit patients.

in intensive care units, it can be much easier to change the environment perception of patients with simple tools such as headphones and sleep bands, rather than changing the environment of the patients. the use of sleep bands and headphones, which are non-pharmacological methods, can reduce sleep deprivation by changing the environmental perception of the patients.

Eligibility criteria:
inclusion criteria: * being 18 years or older, * new york heart association (nyha) functional class ii and iii, * not having received any general anaesthesia for the previous 24 hours, * not having received any sedative medications or opioids for the past 24 hours, * not having a verbal communication disability (hearing and speaking), * absence of pain, * not having a previously diagnosed sleep disorder, * not having psychiatric problems, * not having a cognitive problem, * being healthy enough to put on and take off earplugs independently, in addition to wearing an eye mask and removing it when necessary, and continuing to be hospitalized for at least three days. exclusion criteria: * diagnosed with delirium (intensive care delirium screening checklist \>=5), * unconscious (glasgow coma scale\<13), * presence of additional chronic diseases, * having consumed coffee, alcohol and hypnotic drugs at least 12 hours before the study, * patients whose condition suddenly worsened, * those who cannot use earplugs and eye masks effectively at night, * those who voluntarily withdrew from the study and were transferred from the intensive care unit.

Keywords: intensive care unit headphones sleep bands sleep
romeo (rosuvastatin in metabolic syndrome)

Conditions: Metabolic Syndrome X

Summary: the primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of apob/apoa1 in subjects with metabolic syndrome.


Eligibility criteria:
inclusion criteria: * presence of 3 or more of the following criteria; * abdominal obesity (men \>90cm women \>80cm) * triglycerides ≥ 150 mg/dl * hdl-c: men \< 40 mg/dl, women \< 50 mg/dl * bp ≥130/≥85 mmhg or anti-hypertensive treatment * fasting blood glucose ≥100 mg dl or anti-diabetic treatment * elevated ldl-c ; * ≥130 mg/dl to \< 220 mg/dl in lipid lowering agent naive subjects * ≥100 mg/dl to \< 200 mg/dl in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1. * triglyceride \< 500 mg/dl

Keywords: rosuvastatin lipoprotein metabolic syndrome
based on metabonomics dryness pathogen type of olp: a dynamic study

Conditions: Oral Lichen Planus

Summary: due to the change of life style, the incidence of oral cavity mucous membrane disease increased.in this study，been done a large number of pre-clinical practice and some experimental studies， based on the application of metabolomics technology to ultra-high liquid-mass spectrometry metabolomics analyzer as the core means， the metabolism of pattern recognition and combination of modern analytical techniques to measure blood and urine of patients with olp-specific clearance of endogenous metabolites，and after the intervention of moss drink endogenous metabolites in the body as a whole group of. at the same time， the use of flow cytometry,，elisa， immunohistochemistry and other modern technology, research olp patients using clean moss drink before and after treatment of local lesions and peripheral blood cd4 +，cd8 + lymphocytes，th1 cytokines (ifn-γ， tnf-α)， th2 cytokines (il-4，10) the dynamic changes. from metabolomics， cellular immunology， inflammation mechanism perspective of local olp lesions， peripheral blood and changes in endogenous metabolites in the process,，in-depth study of traditional chinese medicine to drink clean moss multi-component multi-target treatment of this disease mechanism， is widely used in traditional chinese medicine treatment of olp provide a theoretical basis for the promotion of chinese medicine qingxian yin in the oral mucosal disease in the application， effectively solve clinical practice problems.


Eligibility criteria:
inclusion criteria: * all patients with olp . * tcm syndrome of olp patients included is dryness pathogen type. * in the lesions of oral mucosa there are phanerous pearly white keratinization stripes, or patches, or phanerous erosion with the mucous membrane hyperemia. * olp patients may accompany oral coarse discomfort or pain, red tongue, yellow dry or dry fur, dry mouth, bitter taste. exclusion criteria: * patients with other established oral mucosal disease; * patients accompanied by serious systemic diseases, eg damaged liver or kidney functions; or other allergic diseases, eg rheumatic disease or cancer. * patients using the antibiotic in the last one month or immunologic agents in the last three months. * lichenoid reaction caused by drugs or the filling with silver and amalgam. * patients with smoking or alcoholism in the last three months.
exercise and nutrition intervention in ovarian cancer

Conditions: Ovarian Cancer; Malnutrition; Muscle Wasting; Fatigue

Summary: the objective of this multicenter randomized controlled trial is to compare a 6-month exercise and nutrition intervention (intervention group, ig) aimed at maintaining or improving physical functioning and quality of life with usual care (control group, cg) in ovarian cancer patients. the main question it aims to answer is: • can an exercise and nutrition program improve physical performance during and after active treatment for ovarian cancer? participants of the ig will undergo: * weeks 1-18: approximately 15-30 minutes of daily exercise (cardio, resistance, and balance exercises); nutritional counseling focusing on malnutrition (protein-energy malnutrition). * weeks 19-25: more intense daily training; nutritional counseling focusing on the mediterranean diet. the study design includes 3 survey time points: * baseline: after surgery and before starting chemotherapy * t1: after chemotherapy (week 19) * t2: after intervention (week 26) the primary outcome is: • 6-minute walk test, 6 months after enrollment (t2)


Eligibility criteria:
inclusion criteria: * patients with figo ii-iv stage ovarian, fallopian tube, or peritoneal carcinoma * patients must be treated with surgery and chemotherapy * patients receiving adjuvant or neoadjuvant chemotherapy but not yet started exclusion criteria: * patients with an eastern cooperative oncology group (ecog) performance status greater than 2 * patients with inadequate german language skills * patients with physical or mental impairments that make it impossible to perform the training programs or study procedures
treatment of misophonia: comparison of exposure and sound therapy

Conditions: Misophonia

Summary: the goal of this clinical trial is to compare the effects of possible treatments in misophonics. the main question it aims to answer is: - is exposure more effective on misophonic symptoms than sound therapy? participants are randomly assinged to three groups of treatment; 1. psychoeducation 2. psychoeducation + exposure 3. psychoeducation + sound therapy


Eligibility criteria:
inclusion criteria: * people have misophonia exclusion criteria: * current psychosis * mental retardation or dementia * those who had previously received exposure or sound therapy for misophonia symptoms.

Keywords: misophonia sound therapy exposure psychoeducation treatment
prevalence and recognition of geriatric syndrome in outpatient clinic at srinagarind hospital

Conditions: Dementia; Cognitive Impairment; Depression; Urinary Incontinence; Constipation; Falls

Summary: the purpose of this study is to collect the prevalence of geriatric syndrome, which is recognized by an internist, and to compare the data based on the comprehensive geriatric assessment by a geriatrician. the secondary outcome is to develop a practical collected form for the internist.


Eligibility criteria:
inclusion criteria: * all patients who are over than 60 years old who visit internal medicine outpatient clinic

Keywords: geriatric syndrome immobility
effects of pregnancy and childbirth on pelvic floor morphology and sexual function in egyptian women

Conditions: Pregnancy, Childbirth and Puerperal Disorders

Summary: to evaluate levator ani muscle morphology following normal vaginal delivery and cesarean section (elective and emergent), using three-dimensional (3d) transperineal ultrasound, and to study the effect of mode of delivery on female sexual function.

1. transperineal pelvic floor ultrasound applied for the submitted 120 women "primiparae" (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology. 2. answering of the validated female sexual function index (f.s.f.i) three months postpartum period for same cases submitted to ultrasound.

Eligibility criteria:
inclusion criteria: * primiparae in early postpartum period (48 hours to72 hours). written consent was taken. easy communicable, reachable women for further requirements. exclusion criteria: 1. refused consent. 2. previous vaginal or cesarean delivery. 3. severe mental illness. 4. severe physical handicap or difficulties in communication. 5. women without postpartum active sexual life or separate from their spouse. 6. past history of sexual dysfunction.
dispensing study to assess the visual performance of optimised prototype contact lenses

Conditions: Presbyopia; Refractive Error

Summary: the aim of this study is to assess the visual performance of multiple optimised prototype soft contact lens designs compared to commercially available contact lenses.

prospective, double-masked, crossover, bilateral wear, dispensing clinical trial where participants will wear multiple prototype (test) and commercial (control) lenses. multiple prototype contact lens designs will be assessed against commercial control lenses during the study, where each design will be worn for up to a week. there will be a minimum 1 night washout period between lens designs.

Eligibility criteria:
inclusion criteria: * able to read and comprehend english and give informed consent as demonstrated by signing a record of informed consent. * be at least 18 years old, male or female. * willing to comply with the wearing and clinical trial visit schedule as directed by the investigator. * have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses. * is correctable to at least 6/12 (20/40) or better in each eye with contact lenses. * be suitable and willing to wear contact lenses. exclusion criteria: * any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses. * any systemic disease that adversely affects ocular health e.g. diabetes, graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, sjogrens syndrome and systemic lupus erythematosus. conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. * use of or a need for concurrent category s3 and above ocular medication at enrolment. ocular medication can be prescribed during the course of the trial as per standard optometric practice. * use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. note: systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used. * eye surgery within 12 weeks immediately prior to enrolment for this trial. * previous corneal refractive surgery. * contraindications to contact lens wear. * known allergy or intolerance to ingredients in any of the clinical trial products.

Keywords: presbyopia refractive error contact lens
effect of location of tetanic stimuli on photoplethysmogram under general anesthesia

Conditions: Stress Reaction

Summary: the effect of the location of tetanic stimulus on photoplethysmography signals will be studied in patients under general anesthesia.

a 5 second 100 hz 70 ma tetanic stimulus will be applied to three different locations (ulnar nerve, facial nerve, posterior tibial nerve) in a random order in patients who are under general anesthesia. tetanic stimuli are used routinely during general anesthesia to assess effectiveness of neuromuscular blockade. these tetanic stimuli are noxious stimuli that elicit a stress response which can be quantified using photoplethysmography. this study investigates if the magnitude of the tetanus induced stress response is dependent on the location of the tetanic stimulus as measured by photoplethysmography.

Eligibility criteria:
inclusion criteria: * surgical patients * undergoing general anesthesia * able to consent in english * 18 years of age or older exclusion criteria: * under 18 years of age * unable to consent in english * receiving regional anesthesia

Keywords: photoplethysmography stress response